This company listing is no longer active
Kazia Therapeutics Dirección
Dirección controles de criterios 0/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
John Friend
Chief Executive Officer (CEO)
AU$1.6m
Compensación total
| Porcentaje del salario del CEO | 47.1% |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 1.3yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | AU$2m | AU$743k | -AU$20m |
| Mar 31 2023 | n/a | n/a | -AU$23m |
| Dec 31 2022 | n/a | n/a | -AU$25m |
| Sep 30 2022 | n/a | n/a | -AU$25m |
| Jun 30 2022 | AU$1m | AU$430k | -AU$25m |
Compensación vs. Mercado: La compensación total de John($USD1.03M) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD289.12K).
Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.
CEO
John Friend (53 yo)
less than a year
Permanencia
AU$1,576,913
Compensación
Dr. John E. Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Medic...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Interim Chairman | less than a year | AU$1.58m | sin datos | |
| Chief Financial Officer | 1.8yrs | AU$1.05m | sin datos | |
| Company Secretary | less than a year | sin datos | sin datos |
0.8yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de KZA no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Interim Chairman | less than a year | AU$1.58m | sin datos | |
| Independent Non-Executive Director | 8.4yrs | AU$94.00k | 0.36% A$ 68.5k | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 11yrs | AU$94.00k | 0.42% A$ 79.4k | |
| Director | less than a year | AU$7.12k | sin datos | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos |
1.3yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de KZA no se considera experimentada (1.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.